Drugs Made In America Acquisition (DMAA) Income Statement (2024 - 2026)
Income Statement report data from Jun 30, 2024 to Mar 31, 2026 for Drugs Made In America Acquisition (DMAA).
All data is split-adjusted. You can find the most accurate data from the reports on the SEC official website. We recommend verify information using official company filings before making investment decisions.
Reported currency: USD
| Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Jun 30, 2024 | |
|---|---|---|---|---|---|
Operating Expenses | |||||
Selling General And Administrative | 140K (-93.30%) | 2.09M (+703.85%) | 260K (+100.00%) | 130K | - |
Operating Expenses | 140K (-93.30%) | 2.09M (+703.85%) | 260K (+100.00%) | 130K | - |
Operating Income | |||||
Operating Income | -140.00K (-93.30%) | -2.09M (+703.85%) | -260.00K (+100.00%) | -130.00K | - |
EBITDA | -140.00K | - | -260.00K (+100.00%) | -130.00K | - |
Other Income / Expenses | |||||
Interest Income | 2.11M (-8.26%) | 2.30M (-6.12%) | 2.45M (+1.24%) | 2.42M | - |
Net Interest Income | 2.11M (-8.26%) | 2.30M (-6.12%) | 2.45M (+1.24%) | 2.42M | - |
Net Income | |||||
Income Before Tax | 1.97M (+838.10%) | 210K (-90.37%) | 2.18M (-4.80%) | 2.29M | - |
Net Income From Continuing Operations | 1.97M (+838.10%) | 210K (-90.37%) | 2.18M (-4.80%) | 2.29M | - |
Net Income | 1.97M (+838.10%) | 210K (-90.37%) | 2.18M (-4.80%) | 2.29M | - |